A recent enforcement memo from the U.S. Food and Drug Administration (FDA) signals that the agency will not block a new federal initiative allowing certain hemp-derived cannabidiol (CBD) products to be covered under a Medicare plan — a major change in how these products are treated at the federal level.Under the memo, eligible Medicare patients may be able to receive up to $500 … [Read more...] about FDA Memo Paves Way for CBD to Be Covered by Medicare
FDA
The CBD Party’s Ending—FDA Just Flipped the Lights On
For years, CBD has been living its best life in a regulatory gray zone—sold everywhere, claimed to do everything, and barely bothered by the people in charge. That era might be coming to an end.The FDA just made a quiet but meaningful move, sending a new CBD compliance and enforcement policy to the White House for review. It’s not a full-blown rulebook yet, but it’s the … [Read more...] about The CBD Party’s Ending—FDA Just Flipped the Lights On
FDA Chief Acknowledges Medical Benefits Of Cannabis While Warning Of Risks
The head of the U.S. Food and Drug Administration says marijuana may offer meaningful therapeutic value for certain patients, even as federal officials continue to raise concerns about potential health risks — particularly among young users.During a recent television interview, FDA Commissioner Marty Makary emphasized that the administration is balancing two priorities: … [Read more...] about FDA Chief Acknowledges Medical Benefits Of Cannabis While Warning Of Risks
Trump’s Hemp Headache: FDA Scrambles to Finish the Rules He Signed
The FDA is racing a deadline tied to a law Donald Trump signed, and the hemp industry is watching closely. The agency has to publish official lists of cannabinoids and explain what counts as a hemp product “container”—details that could decide what products stay legal.This all traces back to the spending law Trump signed in late 2025, which rewrites the federal definition of … [Read more...] about Trump’s Hemp Headache: FDA Scrambles to Finish the Rules He Signed
MMJ’s FDA-First Cannabis Pharmaceutical Model Thrives Amid DEA Regulatory Gridlock
While the U.S. cannabis industry grapples with regulatory stagnation, companies are diverging in their responses to the political gridlock. Green Thumb Industries CEO Ben Kovler recently voiced frustration over federal inertia, criticizing agencies like the DEA as "out of touch" and resistant to reform. Yet, amid this uncertainty, MMJ International Holdings has charted a … [Read more...] about MMJ’s FDA-First Cannabis Pharmaceutical Model Thrives Amid DEA Regulatory Gridlock
CBD Injections? Hard Pass – FDA Slams Injectable CBD, And Honestly, They Have a Point
Look, I love cannabis as much as the next rational human, but injecting CBD? That’s a hard no. The FDA just put the company Pico IV on blast for selling injectable CBD, and for once, I’m with them. This isn’t innovation—it’s stupidity in a syringe.CBD works just fine in oils, edibles, and topicals. Who looked at a perfectly good tincture and thought, “You know what this needs? … [Read more...] about CBD Injections? Hard Pass – FDA Slams Injectable CBD, And Honestly, They Have a Point
FDA greenlights study of marijuana as PTSD treatment for veterans
The Food and Drug Administration (FDA) has given the go-ahead for a controversial clinical trial to test whether marijuana can be used to treat combat veterans with post-traumatic stress disorder (PTSD). The long-delayed study is sponsored by the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) and had been delayed since 2021 due to several objections by … [Read more...] about FDA greenlights study of marijuana as PTSD treatment for veterans
FDA authorizes clinical trials to study cannabis use for veterans with PTSD
WASHINGTON — The Food and Drug Administration has authorized a non-for-profit company in California to proceed with clinical trials to study the effectiveness of smoking cannabis to treat post-traumatic stress disorder in veterans. MAPS — the Multidisciplinary Association for Psychedelic Studies — will initiate the short-term study of veterans who will smoke marijuana and … [Read more...] about FDA authorizes clinical trials to study cannabis use for veterans with PTSD
New FDA Report Highlights How Marijuana Rescheduling Review Analyzed Cannabis Users’ Social Media Posts
In another letter in December, 29 former U.S. attorneys called on the Biden administration to leave cannabis in Schedule I. Also that month, the governors of six U.S. states—Colorado, Illinois, New York, New Jersey, Maryland and Louisiana—sent a letter to Biden calling on the administration to reschedule marijuana by the end of last year. Meanwhile, six former DEA heads and … [Read more...] about New FDA Report Highlights How Marijuana Rescheduling Review Analyzed Cannabis Users’ Social Media Posts
How this proposed change could dramatically shift U.S. marijuana policy
The Biden administration is considering a major shift in the federal government’s policy on marijuana. In late August, the Department of Health and Human Services recommended that the Drug Enforcement Administration reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act. The Food and Drug Administration has also concluded that marijuana should … [Read more...] about How this proposed change could dramatically shift U.S. marijuana policy
